Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM3J5I
|
|||
| Drug Name |
BI 1467335
|
|||
| Synonyms |
PXS-4728A; 1478364-68-9; BI-1467335 HCl; UNII-6W2049SJPH; 6W2049SJPH; PXS 4728A; 1478364-68-9 (HCl); (E)-4-((2-(Aminomethyl)-3-fluoroallyl)oxy)-N-(tert-butyl)benzamide hydrochloride; PXS 4728 HCl; BI-1467335 hydrochloride; CHEMBL3897599; SCHEMBL16766775; EX-A4639; AC-31510; Benzamide, 4-(((2E)-2-(aminomethyl)-3-fluoro-2-propen-1-yl)oxy)-N-(1,1-dimethylethyl)-, hydrochloride (1:1); HY-112726; CS-0062985; Q27265609; (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic retinopathy [ICD-11: 9B71.0; ICD-10: H36.0] | Discontinued in Phase 2 | [1] | |
| Company |
Boehringer Ingelheim
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C15H22ClFN2O2
|
|||
| Canonical SMILES |
CC(C)(C)NC(=O)C1=CC=C(C=C1)OCC(=CF)CN.Cl
|
|||
| InChI |
1S/C15H21FN2O2.ClH/c1-15(2,3)18-14(19)12-4-6-13(7-5-12)20-10-11(8-16)9-17;/h4-8H,9-10,17H2,1-3H3,(H,18,19);1H/b11-8+;
|
|||
| InChIKey |
AEMZEDNMNLIDSL-YGCVIUNWSA-N
|
|||
| CAS Number |
CAS 1478364-68-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Membrane copper amine oxidase (AOC3) | Target Info | Inhibitor | [1] |
| BioCyc | Phenylethylamine degradation I | |||
| Spermine and spermidine degradation I | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| beta-Alanine metabolism | ||||
| Metabolic pathways | ||||
| Panther Pathway | Phenylethylamine degradation | |||
| Pathwhiz Pathway | Beta-Alanine Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Boehringer Ingelheim. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.